MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$989,708K
Net Income
$44,762K
Net Profit Margin
4.52%
EPS
$0.23
Unit: Thousand (K) dollars
Revenue Breakdown
VOXZOGO
VIMIZIM
NAGLAZYME
Others
Revenue Breakdown
US
Europe
Rest Of World
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
989,708
766,208
874,565
776,133
Cost of sales
202,795
194,999
275,709
140,085
Research and development
206,952
178,796
192,413
409,478
Selling, general and administrative
395,549
258,290
446,207
268,415
Intangible asset amortization
73,492
4,483
4,846
4,847
Gain on sale of nonfinancial assets
-
-
0
0
Total operating expenses
878,788
636,568
919,175
822,825
Income from operations
110,920
129,640
-44,610
-46,692
Interest income
10,480
22,560
19,210
17,854
Interest expense
63,295
14,958
2,778
2,579
Other income, net
3,279
3,961
1,025
5,093
Income before income taxes
61,384
141,203
-27,153
-26,324
Provision for income taxes
16,622
35,676
19,420
4,420
Net income
44,762
105,527
-46,573
-30,744
Basic EPS
0.23
0.55
-0.242
-0.16
Diluted EPS
0.23
0.54
-0.228
-0.16
Basic Average Shares
193,423,000
192,497,000
192,242,000
192,032,000
Diluted Average Shares
194,467,000
197,671,000
203,979,000
192,032,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
VOXZOGO
$252,528K
(14.06%↑ Y/Y)
VIMIZIM
$194,371K
(-9.77%↓ Y/Y)
NAGLAZYME
$135,255K
(4.96%↑ Y/Y)
PALYNZIQ
$135,167K
(27.59%↑ Y/Y)
GALAFOLD
$105,748K
BRINEURA
$51,370K
(5.50%↑ Y/Y)
ALDURAZYME
$43,539K
(-22.85%↓ Y/Y)
POMBILITIOPFOLDA
$30,258K
KUVAN
$24,444K
(-9.58%↓ Y/Y)
ROCTAVIAN
$11,713K
(27.33%↑ Y/Y)
Product
$984,393K
(21.08%↑ Y/Y)
Royalty And Other
$5,315K
(-57.23%↓ Y/Y)
Total revenues
$989,708K
(19.91%↑ Y/Y)
Income from operations
$110,920K
(-59.94%↓ Y/Y)
Interest income
$10,480K
(-44.34%↓ Y/Y)
Other income, net
$3,279K
(-32.15%↓ Y/Y)
Total operating
expenses
$878,788K
(60.21%↑ Y/Y)
Income before income
taxes
$61,384K
(-79.39%↓ Y/Y)
Interest expense
$63,295K
(2262.64%↑ Y/Y)
Selling, general and
administrative
$395,549K
(70.29%↑ Y/Y)
Research and development
$206,952K
(28.30%↑ Y/Y)
Cost of sales
$202,795K
(35.12%↑ Y/Y)
Intangible asset
amortization
$73,492K
(1416.55%↑ Y/Y)
Net income
$44,762K
(-81.39%↓ Y/Y)
Provision for income taxes
$16,622K
(-71.01%↓ Y/Y)
Buy us a coffee
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)